Clinical laboratory assays for measuring anti-dsDNA antibodies. Where are we now?

Lupus

Volumn 11, Issue 12, 2002, Pages 797-800

  Isenberg, D ^a   Smeenk, R ^b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b CENTRAL LABORATORY   (Netherlands)

Author keywords

Anti dsDNA; Antibodies; Lupus activity; SLE

Indexed keywords

DNA ANTIBODY; DOUBLE STRANDED DNA; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; CLINICAL FEATURE; CLINICAL LABORATORY; COMPLEMENT FIXATION; CONFERENCE PAPER; CORRELATION ANALYSIS; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOFLUORESCENCE TEST; PASSIVE HEMAGGLUTINATION; PRECIPITATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, ANTINUCLEAR; DNA; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 0036949955     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203302lu300rr     Document Type: Conference Paper

References (28)

1. Gharavi AE, Chu JL, Elkon KB. Autoantibodies to intracellular proteins in human systemic lupus erythematosus are not due to random polyclonal B cell activation. Arthritis Rheum 1988; 31: 1337-1345.
2. Miescher P, Straessle R. New serological methods for the detection of LE factor. Vox Surg 1957; 2: 283-287.
3. Ceppelini R, Polli E, Celada F. A DNA-reaction factor in serum of a patient with lupus erythematosus diffusus. Proc Soc Exp Biol Med 1957; 96: 572-574.
4. Robbins WC, Holman HR, Deicher H et al. Complement fixation with cell nuclei and DNA in lupus erythematosus. Proc Soc Exp Biol 1957; 9: 575-579.
5. Seligmann M. Evidence in the serum of patients with systemic lupus erythematosus of a substance producing a precipitation reaction with DNA. (Original in French.) C R Soc Biol (Paris) 1957; 245: 328-333.
6. Gladman DD, Urowitz M, Keystone EC. Serologically active, clinically quiescent systemic lupus erythematosus. Am J Med 1979; 66: 210-214.
7. Liang MM, Sacher SA, Roberts WN, Esdaile JM. Measurement of systemic lupus erythematosus activity in clinical research. Arthritis Rheum 1988; 31: 817-825.
8. Bombardier C, Gladman D, Urowitz MB et al. The development and validation of the SLE Disease Activity Index (SLEDAI). Arthritis Rheum 1992; 35: 630-640.
9. Vitali C, Bencivelli W, Isenberg DA et al. Disease activity in systemic lupus erythematosus: report of the consensus study group of the European workshop for rheumatology research. Clin Exp Rheumatol 1992; 10: 541-547.
10. Gladman DD, Goldsmith CH, Urowitz MB et al. Sensitivity to change or 3 systemic lupus erythematosus disease activity indices: international validation. J Rheumatol 1994; 21: 1468-1471.
11. Isenberg DA, Ramsey-Goldman R. Assessing patients with lupus: towards a drug responder index. Rheumatology 1999; 38: 1045-1049.
12. Symmons DPM, Coppock JS, Bacon PA et al. Development of a computerised index of clinical disease activity in systemic lupus erythematosus. Q J Med 1988; 69: 927-932.
13. Hay EM, Bacon PA, Gordon C et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86: 447-458.
14. Isenberg D, Garton M, Reichlin MW, Reichlin M. Long term follow-up of autoantibody profiles in black female lupus patients and clinical comparison with Caucasian and Asian patients. Br J Rheum 1997; 36: 229-233.
15. Isenberg DA, Gordon C. From BILAG to BLIPS - disease activity assessment in lupus past, present and future. Lupus 2000; 9: 651-654.
16. Ho A, Magder L, Barr S, Petri M. Decreases in anti-double stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2342-2349.
17. Isenberg DA, Ehrenstein MR, Longhurst C, Kalsi JK. The origin, sequence, structure and consequences of developing anti-DNA antibodies - a human perspective. Arthritis Rheum 1994; 37: 169-180.
18. Isenberg DA, Ducheney C, Williams W et al. Measurement of anti-DNA antibodies: a reappraisal using five methods. Ann Rheum Dis 1987; 46: 448-456.
19. Smeenk RJT. Measurement of antibodies to DNA. In Venrooij MJv, Maini RN (eds). Manual of Biological Markers of Disease. Kluwer Academic: Dordrecht, 1993, A8, pp 1-12.
20. Smeenk R, Brinkman K, Van den Brink H, Swaak T. A comparison of assays used for the detection of antibodies to DNA. Clin Rheumatol 1990; 9(Suppl 1): 63-72.
21. Brinkman K, Termaat R-M, Brink HGvd, Berden JHM, Smeenk RJT. The specificity of the anti-dsDNA ELISA. A closer look. J Immunol Meth 1991; 139: 91-100.
22. Emlen W, Jarusiripipat P, Burdick G. A new ELISA for the detection of double-stranded DNA antibodies. J Immunol Meth 1990; 132: 91-101.
23. Hylkema MN, Huygen H, Kramers C, Wal ThJvd, Jong Jd, Bruggen MCJv et al. Clinical evaluation of a modified ELISA, using photobiotinylated DNA, for the detection of anti-DNA antibodies. J Immunol Meth 1994; 170: 93-102.
24. Gonzalez C, Pascual MK, Gonzalez-Buitrago JM. Lack of crossreactivity of anti-DNA antibodies to ribonucleoproteins in a new commercial blot system for specific ANAs. Autoimmunity 2000; 32: 129-132.
25. Joos TO, Schrenk M, Hopfl P et al. A microarray enzyme-linked immunosorbent assay for autoimmune diagnostics. Electrophoresis 2000; 21: 2641-2650.
26. Hylkema MN, Bruggen MCJv, Hove Tt, Jong Jd, Swaak AJG, Berden JHM et al. Histone-containing immune complexes are to a large extent responsible for anti-dsDNA reactivity in the Farr assay of active SLE patients. J Autoimmun 2000; 14: 159-168.
27. Feltkamp TEW, Kirkwood TBL, Maini RN, Aarden LA. The first international standard for antibodies to dsDNA. Ann Rheum Dis 1988; 47: 740-746.
28. Bootsma H, Spronk P, Derksen R, Boer Gd, Wolters-Dicke H, Hermans J et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995; 345: 1595-1599.